April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

AACR data propel Syndax shares

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) rose $7.99 (69%) to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613 that showed responses in two out of three patients with acute leukemias that harbor an MLL1 rearrangement. Data for the first-in-class selective inhibitor of Menin-MLL binding interaction were presented at the American Association for Cancer Research virtual meeting...